Image Source: Unsplash
An Introduction
This article highlights the 10 clinical-stage AI-powered (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances the first of May week, in descending order, and YTD and their areas of focus, along with their latest news, analyses and commentary where available.
- focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Latest news, commentary and/or analysis:
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD)
- reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Latest news, commentary and/or analysis: None
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
- focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Latest news, commentary and/or analysis: None
- specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Latest news, commentary and/or analysis:
- Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
- has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Latest news, commentary and/or analysis:
- Nvidia Owns a 3.4% Stake in AI Stock Recursion Pharmaceuticals
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest news, commentary and/or analysis:
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
- develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Latest news, commentary and/or analysis:
- Insider Stock Buying Reaches US$1.61m On AbCellera Biologics
- focuses on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
- specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Latest news, commentary and/or analysis:
- Schrödinger Reports First Quarter 2024 Financial Results
Summary
On average, the above 10 stocks were up 7.4% during the first week of May but are now down 7.6% YTD.More By This Author:Cannabis Stocks Dropped 19%, On Average, In Last 3 Days Of This Week
Déjà Vu: Cannabis Stocks Soared 35%, On Average, Tuesday – Here’s Why
April Recap: Small Cap AI Stocks Portfolio Dropped 23%
